Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

SLC35F5 Inhibitors

SLC35F5 inhibitors are a class of chemical compounds designed to selectively target and inhibit the function of solute carrier family 35 member F5 (SLC35F5), a protein that is part of the larger SLC family responsible for transporting a variety of molecules across cellular membranes. While the precise physiological role of SLC35F5 is not as well-characterized as some other members of the SLC family, it is thought to play a role in the transport of nucleotides, sugars, or other small molecules critical for maintaining intracellular processes. Inhibitors of SLC35F5 are developed to interfere with the protein's ability to mediate the movement of its specific substrates across the membrane. By binding to critical regions of the transporter, these inhibitors block its function, thereby affecting the transport dynamics and altering cellular homeostasis.

The development and characterization of SLC35F5 inhibitors rely on advanced techniques in structural biology and molecular modeling. Researchers study the structure of the SLC35F5 protein to identify potential binding sites where inhibitors can effectively attach and block the transporter's function. Once identified, chemical compounds are designed to interact with these sites, inhibiting the normal translocation of substrates across cellular membranes. These inhibitors are subjected to various in vitro assays to assess their binding affinity, specificity, and inhibitory effects on transport activity. By studying these inhibitors, researchers aim to unravel the specific biological functions of SLC35F5, contributing to a broader understanding of the roles that solute carrier proteins play in cellular processes such as metabolism, energy balance, and intracellular signaling pathways. Through the inhibition of SLC35F5, scientists can explore the implications of altered transport activity and how it impacts cellular and systemic functions.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$26.00
$92.00
$120.00
$310.00
$500.00
$908.00
$1821.00
46
(1)

Isoflavone acting as a tyrosine kinase inhibitor, can interfere with phosphorylation processes, altering signaling pathways that regulate SLC35F5.

Quercetin

117-39-5sc-206089
sc-206089A
sc-206089E
sc-206089C
sc-206089D
sc-206089B
100 mg
500 mg
100 g
250 g
1 kg
25 g
$11.00
$17.00
$108.00
$245.00
$918.00
$49.00
33
(2)

Flavonoid with PI3K inhibitory activity, can disrupt PI3K/Akt signaling, affecting the membrane trafficking and function of SLC35F5.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

MEK inhibitor, can prevent the activation of the MAPK/ERK pathway, potentially impacting SLC35F5 regulation or activity.

Wnt-C59

1243243-89-1sc-475634
sc-475634A
sc-475634B
5 mg
10 mg
50 mg
$210.00
$320.00
$1250.00
1
(0)

Inhibitor of Wnt production, can block Wnt signaling, affecting processes that may regulate SLC35F5 expression or localization.

Dynamin Inhibitor I, Dynasore

304448-55-3sc-202592
10 mg
$87.00
44
(2)

GTPase inhibitor for dynamin, can hinder vesicular trafficking and endocytosis, processes that SLC35F5 may rely on.

Brefeldin A

20350-15-6sc-200861C
sc-200861
sc-200861A
sc-200861B
1 mg
5 mg
25 mg
100 mg
$30.00
$52.00
$122.00
$367.00
25
(3)

Inhibitor of ADP-ribosylation factor, can disrupt Golgi apparatus function, affecting the trafficking and localization of SLC35F5.

2-Deoxy-D-glucose

154-17-6sc-202010
sc-202010A
1 g
5 g
$65.00
$210.00
26
(2)

Glycolysis inhibitor, can alter energy metabolism, potentially affecting the energy-dependent regulation of SLC35F5.

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$152.00
$515.00
(1)

Ionophore that disrupts Golgi function, can impair SLC35F5's glycosylation and trafficking by altering Golgi pH and ion gradients.

Tunicamycin

11089-65-9sc-3506A
sc-3506
5 mg
10 mg
$169.00
$299.00
66
(3)

Inhibitor of N-linked glycosylation, can prevent proper folding and trafficking of SLC35F5 by hindering glycosylation.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Lysosomotropic agent, can raise lysosomal pH, affecting the degradation and turnover of SLC35F5.